Accessibility StatementSkip Navigation NEW YORK, Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? CONTACT US HERE: https://s ...

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeut ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Altimmune, Inc. (NASDAQ:ALT) and SelectQuote, Inc. (NYSE:SLQT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Altimmune, Inc. (NASDAQ:ALT) Class Period: August 10, 2023 to June ...

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025. If you have incurred significant losses and want to act as the lead plaintiff in the class action ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ --Â Levi &Â Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: CONTACT:Levi ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...

Question-and-Answer SessionWith that, we begin the Altimmune fireside chat, and we are excited to have you here. So for those who do not know the story of Altimmune, can you give us a brief background of yourselves and a brief background of the company at a higher level and what you're currently focused on?Vipin GargPresident, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Offic ...

Question-and-Answer SessionWith that, we begin the Altimmune fireside chat, and we are excited to have you here. So for those who do not know the story of Altimmune, can you give us a brief background of yourselves and a brief background of the company at a higher level and what you're currently focused on?Vipin GargPresident, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Offic ...

Altimmune (NasdaqGM:ALT) FY Conference September 10, 2025 07:45 AM ET Company ParticipantsVipin Garg - President, CEO & DirectorM. Scott Harris - Chief Medical OfficerConference Call ParticipantsNone - AnalystNoneHi, everyone. Thank you for joining us today at the fireside chat for Altimmune. I'm very pleased to welcome the President and CEO, Vipin Garg, along with the Chief Medical Officer, Scott Harris. Before we get into the questions, a reminder of our research disclosure. For important disclosures, ple ...

With a background as an RN and an MBA, Stephen analyzes healthcare and tech stocks through the lens of investment process design. His work is guided by his proprietary "Dizzy Framework," a system developed to counter common behavioral errors like chasing market noise or rigidly sticking to priors. By focusing on the quality and timing of information, the framework enforces a patient and disciplined approach, translating complex science and market dynamics into truly actionable theses. His influences include ...